1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Marburg Hemorrhagic Fever - Pipeline Review, H1 2016

Marburg Hemorrhagic Fever - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 91 pages

Marburg Hemorrhagic Fever - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Marburg Hemorrhagic Fever - Pipeline Review, H1 2016’, provides an overview of the Marburg Hemorrhagic Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Marburg Hemorrhagic Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburg Hemorrhagic Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever
- The report reviews pipeline therapeutics for Marburg Hemorrhagic Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Marburg Hemorrhagic Fever therapeutics and enlists all their major and minor projects
- The report assesses Marburg Hemorrhagic Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Marburg Hemorrhagic Fever

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Marburg Hemorrhagic Fever - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Marburg Hemorrhagic Fever Overview 9
Therapeutics Development 10
Pipeline Products for Marburg Hemorrhagic Fever - Overview 10
Pipeline Products for Marburg Hemorrhagic Fever - Comparative Analysis 11
Marburg Hemorrhagic Fever - Therapeutics under Development by Companies 12
Marburg Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes 13
Marburg Hemorrhagic Fever - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Marburg Hemorrhagic Fever - Products under Development by Companies 16
Marburg Hemorrhagic Fever - Products under Investigation by Universities/Institutes 17
Marburg Hemorrhagic Fever - Companies Involved in Therapeutics Development 18
Arbutus Biopharma Corporation 18
Arno Therapeutics, Inc. 19
BioCryst Pharmaceuticals, Inc. 20
Crucell N.V. 21
GeoVax Labs, Inc. 22
GlaxoSmithKline Plc 23
Immunovaccine, Inc. 24
Integrated BioTherapeutics, Inc. 25
NanoViricides, Inc. 26
Profectus BioSciences, Inc. 27
Sarepta Therapeutics, Inc. 28
Marburg Hemorrhagic Fever - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
(Ebola + Marburg) (monovalent) vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
(Ebola + Marburg) (trivalent) vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
(Ebola + Marburg) vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
(Ebola [Sudan, Zaire] + Marburg) vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
1-E703 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Antibodies for Ebola and Marburg Viral Infections - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
AR-12 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
ARD-5 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
AVI-7288 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
BCX-4430 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Ebola vaccine + Marburg vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
FDX-000 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
GOVXE-301 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
GOVXE-302 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
imatinib mesylate - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Marburg vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Marburg vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Monoclonal Antibody for Marburg Virus - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
nilotinib - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Small molecule for Ebola and Marburg Infections - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Small Molecules for Ebola and Marburg Infections - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
TKM-Marburg - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Marburg Hemorrhagic Fever - Recent Pipeline Updates 71
Marburg Hemorrhagic Fever - Dormant Projects 81
Marburg Hemorrhagic Fever - Discontinued Products 82
Marburg Hemorrhagic Fever - Product Development Milestones 83
Featured News and Press Releases 83
Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform 83
Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate 84
Nov 12, 2013: Tekmira Announces New Preclinical Data On TKM-Marburg 84
Oct 08, 2013: Tekmira Provides Corporate Update On RNAi Therapeutics Product TKM-Marburg 85
Sep 25, 2013: Tekmira Presents New Anti-Viral Efficacy Data Against the Marburg Hemorrhagic Fever Virus 86
Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease 87
May 07, 2013: Sarepta Therapeutics Initiates Dosing In Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus 87
Mar 04, 2013: Sarepta Therapeutics's Marburg Drug Shows High Survival Rates After Intramuscular Delivery In Non-Human Primates 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables
Number of Products under Development for Marburg Hemorrhagic Fever, H1 2016 10
Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Marburg Hemorrhagic Fever - Pipeline by Arbutus Biopharma Corporation, H1 2016 18
Marburg Hemorrhagic Fever - Pipeline by Arno Therapeutics, Inc., H1 2016 19
Marburg Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2016 20
Marburg Hemorrhagic Fever - Pipeline by Crucell N.V., H1 2016 21
Marburg Hemorrhagic Fever - Pipeline by GeoVax Labs, Inc., H1 2016 22
Marburg Hemorrhagic Fever - Pipeline by GlaxoSmithKline Plc, H1 2016 23
Marburg Hemorrhagic Fever - Pipeline by Immunovaccine, Inc., H1 2016 24
Marburg Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H1 2016 25
Marburg Hemorrhagic Fever - Pipeline by NanoViricides, Inc., H1 2016 26
Marburg Hemorrhagic Fever - Pipeline by Profectus BioSciences, Inc., H1 2016 27
Marburg Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H1 2016 28
Assessment by Monotherapy Products, H1 2016 29
Assessment by Combination Products, H1 2016 30
Number of Products by Stage and Target, H1 2016 32
Number of Products by Stage and Mechanism of Action, H1 2016 34
Number of Products by Stage and Route of Administration, H1 2016 36
Number of Products by Stage and Molecule Type, H1 2016 38
Marburg Hemorrhagic Fever Therapeutics - Recent Pipeline Updates, H1 2016 71
Marburg Hemorrhagic Fever - Dormant Projects, H1 2016 81
Marburg Hemorrhagic Fever - Discontinued Products, H1 2016 82

List of Figures
Number of Products under Development for Marburg Hemorrhagic Fever, H1 2016 10
Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 29
Assessment by Combination Products, H1 2016 30
Number of Products by Top 10 Targets, H1 2016 31
Number of Products by Stage and Top 10 Targets, H1 2016 31
Number of Products by Top 10 Mechanism of Actions, H1 2016 33
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 33
Number of Products by Routes of Administration, H1 2016 35
Number of Products by Stage and Routes of Administration, H1 2016 35
Number of Products by Molecule Types, H1 2016 37
Number of Products by Stage and Molecule Types, H1 2016 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.